Recruiting Erectile Dysfunction Studies in Newport Beach
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positiv...
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breat...
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan...
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
Multicenter, open-label study in patients with advanced or metastatic solid tumor malignancies to evaluate the safety, tolerability, and preliminary anti-tumor efficacy, PK, and pharmacodynamics of co...
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
INDP-D101 is a Phase 1/2, open-label, multi-center, dose escalation and expansion study evaluating the safety, tolerability and clinical activity of Decoy20 as monotherapy and in combination with tisl...
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely to be cured or controlled with treatment a...
About Erectile Dysfunction Clinical Trials in Newport Beach
Erectile dysfunction is the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It affects about 30 million men in the U.S. and is often a sign of underlying cardiovascular disease. Treatment includes PDE5 inhibitors, vacuum devices, and penile implants.
There are currently 6 erectile dysfunction clinical trials recruiting participants in Newport Beach, CALIFORNIA. These studies are seeking a combined 1,278 participants. Research is being sponsored by AstraZeneca, Regeneron Pharmaceuticals, Boehringer Ingelheim and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Erectile Dysfunction Clinical Trials in Newport Beach — FAQ
Are there erectile dysfunction clinical trials in Newport Beach?
Yes, there are 6 erectile dysfunction clinical trials currently recruiting in Newport Beach, CALIFORNIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Newport Beach?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Newport Beach research site will contact you about next steps.
Are clinical trials in Newport Beach free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Newport Beach studies also compensate for your time and travel.
What erectile dysfunction treatments are being tested?
The 6 active trials in Newport Beach are testing new therapies including novel drugs, biologics, and treatment approaches for erectile dysfunction.
Data updated March 2, 2026 from ClinicalTrials.gov